RecruitingPhase 4NCT06514547

Vaccine Immunity and Inflammation in the Aging Person Living With HIV


Sponsor

Hennepin Healthcare Research Institute

Enrollment

250 participants

Start Date

Jul 8, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining whether HIV-positive adults on antiretroviral therapy have a different immune response to pneumococcal vaccines compared to HIV-negative people, and whether HIV-related inflammation affects vaccine effectiveness. **You may be eligible if...** - You are 18 or older - You are HIV-positive and on antiretroviral therapy with a viral load below 200 in the past year - Controls: HIV-negative individuals aged 18 or older who are willing to have blood drawn **You may NOT be eligible if...** - You have another significant condition that suppresses the immune system - You are under 18 - You are pregnant at enrollment - You have a known contraindication to pneumococcal vaccination - You have severe anemia (hemoglobin below 8 g/dL) - You are currently incarcerated - You are unable to provide consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALConjugate Pneumococcal Vaccine 20 (PCV20)

Vaccine


Locations(1)

Hennepin Healthcare System

Minneapolis, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06514547


Related Trials